Lung cancer organoids: models for preclinical research and precision medicine
Lung cancer is a malignancy with high incidence and mortality rates globally, and it has a 5-year survival rate of only 10%–20%. The significant heterogeneity in clinical presentation, histological features, multi-omics findings, and drug sensitivity among different lung cancer patients necessitate...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1293441/full |
| _version_ | 1797650856727805952 |
|---|---|
| author | Yajing Liu Yajing Liu Yanbing Zhou Pu Chen Pu Chen |
| author_facet | Yajing Liu Yajing Liu Yanbing Zhou Pu Chen Pu Chen |
| author_sort | Yajing Liu |
| collection | DOAJ |
| description | Lung cancer is a malignancy with high incidence and mortality rates globally, and it has a 5-year survival rate of only 10%–20%. The significant heterogeneity in clinical presentation, histological features, multi-omics findings, and drug sensitivity among different lung cancer patients necessitate the development of personalized treatment strategies. The current precision medicine for lung cancer, primarily based on pathological and genomic multi-omics testing, fails to meet the needs of patients with clinically refractory lung cancer. Lung cancer organoids (LCOs) are derived from tumor cells within tumor tissues and are generated through three-dimensional tissue culture, enabling them to faithfully recapitulate in vivo tumor characteristics and heterogeneity. The establishment of a series of LCOs biobanks offers promising platforms for efficient screening and identification of novel targets for anti-tumor drug discovery. Moreover, LCOs provide supplementary decision-making factors to enhance the current precision medicine for lung cancer, thereby addressing the limitations associated with pathology-guided approaches in managing refractory lung cancer. This article presents a comprehensive review on the construction methods and potential applications of LCOs in both preclinical and clinical research. It highlights the significance of LCOs in biomarker exploration, drug resistance investigation, target identification, clinical precision drug screening, as well as microfluidic technology-based high-throughput drug screening strategies. Additionally, it discusses the current limitations and future prospects of this field. |
| first_indexed | 2024-03-11T16:07:46Z |
| format | Article |
| id | doaj.art-d86471e157044f23b0f6a5d9cca180cd |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T16:07:46Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d86471e157044f23b0f6a5d9cca180cd2023-10-24T23:46:37ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-10-011310.3389/fonc.2023.12934411293441Lung cancer organoids: models for preclinical research and precision medicineYajing Liu0Yajing Liu1Yanbing Zhou2Pu Chen3Pu Chen4School of Pharmacy, Qingdao University, Qingdao, ChinaResearch and Development Department, NanoPeptide (Qingdao) Biotechnology Ltd., Qingdao, ChinaDepartment of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaResearch and Development Department, NanoPeptide (Qingdao) Biotechnology Ltd., Qingdao, ChinaDepartment of Chemical Engineering and Waterloo Institute for Nanotechnology, University of Waterloo, Waterloo, ON, CanadaLung cancer is a malignancy with high incidence and mortality rates globally, and it has a 5-year survival rate of only 10%–20%. The significant heterogeneity in clinical presentation, histological features, multi-omics findings, and drug sensitivity among different lung cancer patients necessitate the development of personalized treatment strategies. The current precision medicine for lung cancer, primarily based on pathological and genomic multi-omics testing, fails to meet the needs of patients with clinically refractory lung cancer. Lung cancer organoids (LCOs) are derived from tumor cells within tumor tissues and are generated through three-dimensional tissue culture, enabling them to faithfully recapitulate in vivo tumor characteristics and heterogeneity. The establishment of a series of LCOs biobanks offers promising platforms for efficient screening and identification of novel targets for anti-tumor drug discovery. Moreover, LCOs provide supplementary decision-making factors to enhance the current precision medicine for lung cancer, thereby addressing the limitations associated with pathology-guided approaches in managing refractory lung cancer. This article presents a comprehensive review on the construction methods and potential applications of LCOs in both preclinical and clinical research. It highlights the significance of LCOs in biomarker exploration, drug resistance investigation, target identification, clinical precision drug screening, as well as microfluidic technology-based high-throughput drug screening strategies. Additionally, it discusses the current limitations and future prospects of this field.https://www.frontiersin.org/articles/10.3389/fonc.2023.1293441/fulllung cancer organoidsbiobanksdrug screeningprecision medicinebiomarker exploration |
| spellingShingle | Yajing Liu Yajing Liu Yanbing Zhou Pu Chen Pu Chen Lung cancer organoids: models for preclinical research and precision medicine Frontiers in Oncology lung cancer organoids biobanks drug screening precision medicine biomarker exploration |
| title | Lung cancer organoids: models for preclinical research and precision medicine |
| title_full | Lung cancer organoids: models for preclinical research and precision medicine |
| title_fullStr | Lung cancer organoids: models for preclinical research and precision medicine |
| title_full_unstemmed | Lung cancer organoids: models for preclinical research and precision medicine |
| title_short | Lung cancer organoids: models for preclinical research and precision medicine |
| title_sort | lung cancer organoids models for preclinical research and precision medicine |
| topic | lung cancer organoids biobanks drug screening precision medicine biomarker exploration |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1293441/full |
| work_keys_str_mv | AT yajingliu lungcancerorganoidsmodelsforpreclinicalresearchandprecisionmedicine AT yajingliu lungcancerorganoidsmodelsforpreclinicalresearchandprecisionmedicine AT yanbingzhou lungcancerorganoidsmodelsforpreclinicalresearchandprecisionmedicine AT puchen lungcancerorganoidsmodelsforpreclinicalresearchandprecisionmedicine AT puchen lungcancerorganoidsmodelsforpreclinicalresearchandprecisionmedicine |